Skip to main content

Site notifications

Guideline on clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy

We have adopted this International Scientific Guideline - EMEA/CPMP/555/95 Rev. 1.

Last updated

Help us improve the Therapeutic Goods Administration site